Alnylam Q2 Net Loss Falls Amid Lower R&D Costs

Contributing to the lower loss was a payment to partner Isis made in the second quarter of last year.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.